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RESEARCH NOTE
The PHARMS (Patient Held Active 
Record of Medication Status) feasibility study: a 
research proposal
Elaine Walsh1* , Laura J. Sahm2, Patricia M. Kearney3, Henry Smithson1, David M. Kerins4, Chrys Ngwa5, 
Ciara Fitzgerald6, Stephen Mc Carthy6, Eimear Connolly7, Kieran Dalton8, Derina Byrne9, Megan Carey7 
and Colin Bradley1
Abstract 
Objective: Medication errors are a major source of preventable morbidity, mortality and cost and many occur at 
the times of hospital admission and discharge. Novel interventions (such as new methods of recording medication 
information and conducting medication reconciliation) are required to facilitate accurate transfer of medication 
information. With existing evidence supporting the use of information technology and the patient representing the 
one constant in the care process, an electronic patient held medication record may provide a solution. This study will 
assess the feasibility of introducing a patient held electronic medication record in primary and secondary care using 
the Consolidated Framework for Implementation Research (CFIR).This feasibility study is a mixed method study of 
community dwelling older adult patients admitted to an urban secondary care facility comprising a non-randomised 
intervention and qualitative interviews with key stakeholders. Outcomes of interest include clinical outcomes and 
process evaluation.This study will yield insights pertaining to feasibility, acceptability and participation for a more 
definitive evaluation of the intervention. The study also has the potential to contribute to knowledge of implementa-
tion of technology in a healthcare context and to the broader area of implementation science.
Keywords: Medication error, Transitional care, Medication reconciliation, Information technology, Implementation 
science
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Introduction
Background
Medication errors are a major source of preventable mor-
bidity, mortality and cost [1, 2]. Many errors occur dur-
ing transitional care as patients move between different 
stages and settings of care [3]. Existing evidence suggests 
that medication errors frequently occur at the primary-
secondary care interface, when patients move between 
the hospital and the community at time of admission to 
and discharge from hospital [4, 5]. Errors are particularly 
prevalent among elderly patients taking multiple medica-
tions [6, 7]. Key sources of potential error at this interface 
include legibility, documentation and communication 
between healthcare professionals [8–10].
Medication reconciliation is the formal process for 
identifying and correcting unintentional medication dis-
crepancies during transitional care and is promoted as a 
method to improve patient safety internationally [11–13]. 
The goal of medication reconciliation is to provide the 
patient with an up to date and accurate list of medica-
tions that is available and is reviewed in all settings and 
stages of care [14]. Different strategies used for medica-
tion reconciliation include: a multidisciplinary approach 
[15]; pharmacist-led initiatives [16] and complex mul-
tifaceted interventions [17]. A recent systematic review 
identified a lack of consensus regarding the most effective 
method of medication reconciliation and a lack of reduc-
tion in healthcare utilisation among initiatives to date 
[18].
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Novel interventions are required to optimise medica-
tion reconciliation and to address the issue of medica-
tion error at the primary–secondary care interface. There 
is evidence to suggest that information technology has 
a role in medication reconciliation [19–21], particularly 
medication reconciliation at the primary–secondary 
care interface [22]. General practitioners (GPs) are an 
accurate provider of patients’ medication information 
[23] and hence integration of medication information 
from primary care at time of hospital admission and dis-
charge may facilitate medication reconciliation between 
primary and secondary care. In a consensus statement 
on medication reconciliation Greenwald et al. state that: 
“A personal health record that is integrated and easily 
transferable between sites of care is needed to facilitate 
successful medication reconciliation” [14]. The patient 
represents the one constant in care processes, including 
transitions in care, and hence an electronic patient held 
record of medication using medication information from 
primary care may be a viable option to assist in the pro-
cess of medication reconciliation at the primary second-
ary care interface.
Intervention development and evaluation
The process of developing and introducing a new tech-
nology in a healthcare context is complex. Though the 
benefits of technology in a healthcare context are well 
established, many interventions found to be effective 
in health services research fail to be successfully imple-
mented and hence fail to improve patient care [24]. Bar-
riers to implementation may occur at multiple levels: the 
patient level, the provider level, the organizational level 
or the policy level [25]. To address such issues, the UK 
Medical Research Council (MRC) recommends a struc-
tured methodological approach in developing a com-
plex intervention in the healthcare setting. Systematic 
development is recommended based on best available 
evidence and appropriate theory [26]. The steps recom-
mended in development are outlined in Fig. 1:
Following development, the MRC recommends testing 
of interventions in a phased approach beginning with a 
feasibility study and moving on to exploratory and finally 
definitive evaluation [26].
Existing evidence has identified both the need for novel 
interventions to assist with medication reconciliation and 
the potential of an electronic patient held medication 
record to provide a solution [14, 18, 19]. In accordance 
with such evidence and the MRC methodological frame-
work a secure password protected electronic patient held 
medication record has been developed (Additional file 1). 
The device utilises the Universal Serial Bus (USB) port of 
any computer and provides a link to the patient’s general 
practice medication record. The device acts as a key pro-
viding access to a patient’s medication list as it appears in 
their general practice record with no information being 
stored on the device. Changes to a patient’s medication 
may be documented via this device in secondary care but 
the master list may only be altered by a patient’s GP in 
primary care.
Successful development and implementation of a novel 
intervention within the healthcare setting requires a 
detailed understanding of the context in which it is being 
introduced and potential barriers to implementation. The 
introduction of an electronic Patient Held Active Record 
of Medication status (PHARMS) at the interface of pri-
mary and secondary care involves multiple stakeholders 
(patients, healthcare professionals and information tech-
nology personnel), and two settings of care. To explore 
the issues surrounding development and implementation 
of this novel intervention prior to a definitive evaluation, 
in line with MRC guidance, the Consolidated Frame-
work for Implementation Research (CFIR) will be used. 
The CFIR is a meta-theoretical framework. It combines 
key elements from published implementation theories 
and provides a structure to verify what works, where and 
why across multiple contexts. It consists of five domains. 
Each domain consists of factors and influences which 
impact the degree to which an intervention or practice is 
adopted [27]:
1. Intervention characteristics.
2. Outer setting.
3. Inner setting.
4. Characteristics of the individuals involved.
5. Process of Implementation.
Study objective
This paper outlines the protocol for a feasibility study of 
introducing an electronic patient held medication record 
in primary and secondary care using the CFIR. The study 
1 
Idenfying the exisng 
evidence base 
2
Idenfying and 
developing theory
3
Modelling process and 
outcomes
Fig. 1 Steps of the development stage of a complex intervention outlined in the MRC methodological approach [26]
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aims to examine the performance of the device in addi-
tion to establishing acceptability of the initiative to key 
stakeholders and identifying the barriers and facilitators 
to the process of its implementation.
Main text
Methods
The CONSORT 2010 extension for pilot and feasibility 
trials has been used to inform study methodology [28].
Based on the MRC recommendation of testing an inter-
vention in a phased approach, the study will be conducted in 
two phases as illustrated in Fig. 1.
Phase 1:  introduction of the patient held electronic 
medication record at the interface of pri-
mary and secondary care at time of hospital 
discharge
Phase 2:  introduction of the patient held electronic medi-
cation record at the interface of primary and sec-
ondary care at time of hospital admission.
The findings from Phase 1 will be used to inform the 
Phase 2 of the feasibility study as shown in Fig. 2.
Study design
The feasibility study is a two phase non-randomised con-
trolled intervention study with qualitative and quantita-
tive evaluation components at each phase. Phase 1 will 
involve introduction of a patient held electronic medi-
cation record to the discharge process and Phase 2 will 
involve introduction of a patient held electronic medica-
tion record to the admission process. Realistic evaluation, 
informed by the approach used by Rycroft et al. [29], will 
be conducted by combining an experimental study design 
Research 
queson:
Is the introducon of an 
electronic paent held 
medicaon record  at 
the interface of primary 
and secondary care 
feasible and beneficial?
Phase 1: 
Introducon of a 
paent held electronic 
record to the discharge 
process
Phase 1 evaluaon:
Quantave 
assessment of discharge 
medicaon informaon
Qualitave assessment 
of intervenon 
Process evalutaion 
Phase 2: 
Introducon of a 
paent held electronic 
medicaon record at 
me of  hospital 
admission
Phase 2 evaluaon:
Quantave assessment 
of admission medicaon 
informaon
Qualitave assessment 
of intervenon
Process evaluaon
Fig. 2 Phases of the feasibility study
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with exploratory research in order to identify issues per-
taining to implementation.
Setting
The study will be conducted in the five general medical 
and surgical wards of an urban 350 bed secondary care 
facility and four urban general practices. Following anal-
ysis of referral patterns over a 2-month period, the four 
practices were selected on the basis of having high rates 
of referral to the secondary care facility.
Sample size
A sample size of 65 patients per arm has been calculated. 
Previous work in the same clinical setting has indicated a 
rate of 1.1 medication errors per prescription from a total 
of 1600 prescriptions written with in a similar timescale to 
that envisaged in the feasibility study [30]. A sample size 
of 65 from a population of 1600 prescriptions would be 
capable of providing estimates of the difference in medi-
cation error rates of 10% with a confidence of 90% [31].
Participants
Patients
Community dwelling older adult patients (>  60  years) 
admitted to hospital who are taking three or more medi-
cations will be included in the study.
Exclusion criteria Patients who are resident in long-
term care facilities, who are unable to provide written 
informed consent or who are in receipt of end of life care 
will be excluded from the study.
Staff
Hospital doctors and nurses, General Practitioners (GPs) 
and Information Technology (IT) staff will be involved in 
the study.
Preparation and training
Healthcare professionals
Information regarding the study will be disseminated to 
all clinical staff of the participating secondary care facil-
ity via email in advance of commencing the study. The 
lead researcher (EW) will present at teaching sessions for 
medical, nursing and allied healthcare professional staff. 
Additionally, EW will provide two dedicated training ses-
sions regarding use of the device to the non-consultant 
hospital doctors (NCHDs) of the secondary care facility 
and an education session to each of the four participating 
general practices.
IT
Software will be installed on one computer in each of the 
four participating general practices and on one computer 
on each of the five general hospital wards to enable the 
integration of the patient held medication record into the 
existing primary and secondary care IT systems.
The results of Phase 1 will be used to guide preparation 
for Phase 2. Further dissemination of information and 
education/training sessions will be provided as necessary 
for Phase 2.
Phase 1: Introduction of the patient held active electronic 
medication record at time of hospital discharge
Eligible patients will be identified on all five general medi-
cal and surgical wards of the participating secondary care 
facility. Patients will be provided with an information 
leaflet and written informed consent will be obtained.
Intervention arm
Following hospital admission, eligible patients from the 
four participating GP practices will be assigned to receive 
an electronic patient held medication record. The device 
will be activated and the GP medication list will be linked 
from the electronic patient record in primary care. In 
order to maximise safety and confidentiality the chief 
investigator (EW) will be responsible for both transport 
of the device and linking the device to the patient’s record 
in general practice. General practice, community phar-
macy, hospital admission and hospital discharge medi-
cation information will be collected on all patients and 
patient age, co-morbidities and functional status will be 
recorded. The patient is asked to retain the device dur-
ing their inpatient stay. Intervention patients will be iden-
tified by a sticker on their medical notes, nursing notes 
and drug chart. A note will also be entered by the lead 
researcher (EW) into their medical and nursing notes. At 
time of discharge the patient’s hospital doctor will obtain 
the device from the patient. The doctor will use the 
device to access the patient’s pre admission medication 
list when generating the discharge prescription for the 
patient and to note/explain any alterations made during 
the inpatient stay. The discharge medication information 
and associated explanations of alterations will be com-
municated electronically to the patient’s file in general 
practice at time of generating the discharge prescription. 
This information will appear as a separate electronic doc-
ument in the patient’s file in general practice. A discharge 
prescription will be printed for the patient and the device 
will be returned to the patient’s care at time of hospi-
tal discharge. Following discharge, the patient’s GP will 
be able to access the document in the patient’s file and 
adjust the master medication list accordingly.
Control arm
Following hospital admission eligible patients on all five 
general medical and surgical wards from non-interven-
tion general practices will be identified. General practice, 
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community pharmacy, hospital admission and hospital 
discharge medication information will be collected on 
all patients and age, co-morbidities and functional sta-
tus will be recorded. At the time of discharge this patient 
group will receive usual care in the form of a handwritten 
discharge prescription.
Phase 2: Introduction of the patient held electronic 
medication record at the interface of primary 
and secondary care at time of hospital admission
Eligible patients will be identified by their GP in the four 
participating GP practices at time of referral to the emer-
gency department of the secondary care facility.
Intervention arm
GPs will issue patients with a device and activate the 
device at time of referral to the emergency department. 
The patient will be asked to retain the device and to pre-
sent the device to the staff of the emergency department 
at time of arrival. The staff of the emergency department 
will use the device to access the patient’s pre-admission 
medication list. General practice, community pharmacy, 
hospital admission and hospital discharge medication 
information will be collected on all patients and age, co-
morbidities and functional status will be recorded.
Control arm
Pre-admission and admission medication information 
data from Phase 1 control patients will be used.
Outcomes of interest
Outcomes of interest reflect the CFIR domains and 
include both clinical outcomes and process evaluation. 
The outcomes are based on realistic evaluation firstly, to 
facilitate action research by using the findings of Phase 1 to 
inform Phase 2 and secondly, to develop explanatory the-
ory to inform a future definitive evaluation. Table  1 out-
lines the CFIR domains and the relevant study measures.
Clinical outcomes
Phase 1
Prevalence of prescribing errors will be determined in 
both arms by evaluation of the discharge prescriptions.
Specifically, each prescription will be assessed regarding:
1. Patient demographics and legal requirements.
  • Name and address.
  • Date.
  • Age or date of birth.
  • Prescribers signature.
  • Irish Medical council registration number for the 
prescribing physician.
  • Controlled drug prescription requirements as speci-
fied by the Misuse of Drugs Act [32].
2. Therapeutics.
  • Legibility.
  • Accuracy of spelling.
  • Presence of strength/dose/frequency.
  • Quantity.
  • Presence of repeat items and whether or not this is 
appropriate.
  • Presence of drug–drug interactions as per Stockley’s 
Drug Interactions.
Table 1 CFIR domains and relevant study measures
CFIR domains How the domain aligns with the implementation of the 
electronic patient held medication record
Relevant study measures
Intervention characteristics Relative advantage of device over usual practice
Use of device (design and complexity)
Perceptions of hospital healthcare professional, GPs and 
patients regarding use of the device (qualitative inter-
views)
Non-participant observation
Outer setting Importance as perceived by wider secondary and primary 
care stakeholders
Promotion of use of the device from clinical and adminis-
trative directors/leaders within the participating hospital 
and general practices
Perceptions of hospital healthcare professionals, GPs and 
patients regarding potential of the device (qualitative 
interviews)
Occurrence of medication error (quantitative analysis of 
medication information)
Non-participant observation
Inner setting Readiness for change, quality of communication and 
teamwork within the participating hospital and general 
practices
Perceptions of hospital healthcare professionals, GPs and IT 
staff (qualitative interviews)
Non-participant observation
Individual characteristics Knowledge, beliefs and motivation of individuals involved 
in the study
Perceptions of hospital healthcare professionals, patients 
and GPs (qualitative interviews)
Implementation process Establishing a plan for evaluation on a larger scale
Methods to engage relevant individuals
Perceptions of hospital healthcare professionals, patients, 
GPs and IT staff (qualitative interviews)
Non-participant observation
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The prevalence of prescribing errors in the intervention 
and control groups will be compared.
Phase 2
Prevalence of discrepancies between the pre-admission 
medication information (GP and community pharmacy) 
and the admission medication information as prescribed 
on the patient’s hospital drug chart will be described.
In both phases data will be anonymised, coded and 
entered into an Excel spreadsheet on a password pro-
tected computer. Statistical analysis will be conducted 
using IBM SPSS version 24.
Process evaluation
Qualitative interviews
Semi structured interviews will be conducted in Phase 1 
and Phase 2 with:
1. Hospital healthcare professionals who used the device.
2. Patients who were issued with devices.
3. GPs of patients issued with devices.
4. IT professionals involved in primary and secondary 
care.
A census sample of hospital healthcare profession-
als, GPs and IT professionals will be sought. Sampling 
of patients will be purposive and will aim to ensure ade-
quate representation of demographics such as age, gen-
der and socioeconomic status. Descriptive statistics will 
be applied to demographic information. Interviews will 
be conducted until data saturation is reached [33].
Interviews will be recorded, transcribed and coded. 
Dual independent coding and thematic analysis will be 
conducted. Preliminary analysis will run concurrently 
with data collection and the topic guide will be amended 
as necessary. Data will be managed using N Vivo software 
on a password protected computer.
Non‑participant observation
Direct observation of the implementation process will be 
conducted to identify barriers and facilitators [34]. Sig-
nificant events such as medication interactions or omis-
sions will be noted and medical staff of the participating 
care facilities informed. Observations will be recorded as 
field notes.
Ethical issues
Written informed consent will be obtained from all par-
ticipants. In view of the inclusion of potentially vulnera-
ble older patients in the study, ability to provide informed 
consent will be assessed on a case by case basis, liaising 
with medical/nursing staff and family members where 
appropriate.
To limit any possible loss of confidential information, 
security has been a priority in device development and 
the device is protected to the highest level. Additionally, 
patient information accessed via the device has been lim-
ited to medication information.
Discussion
Medication error during transitional care is an important 
patient safety issue and establishing effective medica-
tion reconciliation strategies is currently an international 
priority [11–13]. Benefit has been demonstrated with 
use of electronic systems of medication reconciliation 
during transitional care [19, 21, 22, 35]. Prior research 
has highlighted firstly the importance of integration of 
medication information between primary and second-
ary care [35] and secondly the need for multidisciplinary 
and patient involvement [35, 36]. To date there is no con-
sensus regarding the most effective method [18] and the 
patient held electronic medication record represents a 
novel method of electronic medication reconciliation. It 
has the potential to harness the proven benefit of elec-
tronic medication reconciliation in addition to providing 
a novel method of integration of medication information 
between primary and secondary care. It has the addi-
tional potential to empower the patient within the medi-
cation reconciliation process. However, the development 
and implementation of a new technology in the health-
care setting at the interface of primary and secondary 
care presents multiple challenges. It is anticipated that 
the use of the CFIR in combination with clinical and real-
istic evaluation in this feasibility study will yield insights 
for a further more definitive evaluation of the electronic 
patient held medication record. The results of this study 
will be used to inform the design of a randomised con-
trolled trial. Specifically, information will be obtained 
regarding feasibility, acceptability, participation rates 
and loss to follow up to inform a future trial. In addition, 
this study has the potential to contribute to knowledge 
of implementation of technology in a healthcare context 
and to the broader area of implementation science.
Limitations
This feasibility study is a small scale study limited to a 
single secondary care site. Additionally, the intervention 
will not be introduced in community pharmacies in this 
study. Further work will be required to explore introduc-
tion of the device in multiple sites and the potential for 
use in the community pharmacy context.
Additional file
Additional file 1. Patient held medication record. Additional detail on 
mechanism of patient held medication record.
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